Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Much of this was due to a very well-received quarterly earnings report.
Overview
Bausch Health Companies (NYSE: BHC) had quite a scorching July as far as its stock was concerned. It was bookended by a regulatory win in Canada for the pharmaceutical conglomerate and a beat-and-raise quarterly earnings report. This propelled the stock to a nearly 40% gain over the month.
On July 6, Bausch announced that its Prokedi schizophrenia drug for adult patients had been added to the Quebec Health Insurance Board's formulary.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.